• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Establishment of therapeutic strategies based on the understanding of cancer stemness regulated by gain-of-function mutant p53

Research Project

Project/Area Number 22K19577
Research Category

Grant-in-Aid for Challenging Research (Exploratory)

Allocation TypeMulti-year Fund
Review Section Medium-sized Section 55:Surgery of the organs maintaining homeostasis and related fields
Research InstitutionKyushu Central Hospital of the Mutual Aid Association of Public School Teachers

Principal Investigator

maehara yoshihiko  公立学校共済組合九州中央病院(臨床研究センター), 臨床研究センター, 主任研究員 (80165662)

Co-Investigator(Kenkyū-buntansha) 北尾 洋之  福岡歯科大学, 口腔歯学部, 教授 (30368617)
飯森 真人  福岡歯科大学, 口腔歯学部, 准教授 (20546460)
沖 英次  九州大学, 医学研究院, 准教授 (70380392)
Project Period (FY) 2022-06-30 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2023: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2022: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Keywords機能獲得型p53変異 / p53変異細胞株パネル / 遺伝子発現プロファイル / エピゲノム異常 / 癌幹細胞化 / p53機能獲得型変異 / p53機能獲得型変異 / 癌の浸潤・転移
Outline of Research at the Start

再発と転移は癌の克服を難しくさせているが,原因の一つに抗癌剤治療に抵抗性を示す癌幹細胞が考えられる。癌の癌幹細胞化のメカニズムのひとつにエピゲノム異常が関与すると考えられ,癌抑制遺伝子p53機能獲得型変異体がエピゲノム異常を起こすことで癌の増殖を亢進させることが報告された。本研究はp53変異体が癌幹細胞化にどのような影響を与えるかを基礎研究で明らかにし,さらに臨床検体による大型コホートを用いてp53変異と癌幹細胞の関連性を明らかにすることで,p53変異ステータスが癌幹細胞の特性決定に起因するという従来とは全く異なる視点からの新規癌幹細胞形成モデルの提唱に挑戦する。

Outline of Final Research Achievements

In this study, we attempted to propose a novel model of cancer stem cell formation, in which gain-of-function p53 is responsible for determining the characteristics of cancer stem cell.
First, we generated a panel of p53 mutant cell lines using genome editing system, and RNA-seq analysis revealed altered gene expression profiles in gain-of-function p53 mutant cells. Furthermore, gene ontology enrichment analysis revealed a characteristic variation between p53-deficient and gain-of-function mutants, which may be useful to verify the cancer stemness of p53 gain-of-function mutants.Further validation using a panel of p53 mutant cell lines showed that the nucleoside analogue FTD had a cytotoxic effect without the influence of the gain-of-function p53 gene.

Academic Significance and Societal Importance of the Research Achievements

本研究で構築したp53変異細胞株パネルは,p53遺伝子変異以外の要因を排除するために野生型p53遺伝子をもつHCT116細胞を親株としてゲノム編集技術により樹立されたアイソジェニックな細胞パネルである。これはp53ステータスの違い(野生型,欠損型,機能獲得型)がもたらす影響を解析する研究に対して有力なツールとなる。機能獲得型p53変異は放射線やある種の抗がん剤耐性に寄与することが報告されるが,本細胞パネルによる検証ではヌクレオシドアナログ系抗がん剤FTDは機能獲得型p53変異の影響を受けずに殺細胞効果を発揮することが示され,p53ステータスの違いが治療効果におよぼす影響の予測に有用である。

Report

(3 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • Research Products

    (12 results)

All 2024 2023 2022

All Journal Article (6 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results) Presentation (6 results)

  • [Journal Article] Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)2023

    • Author(s)
      Ando Koji、Nakamura Yoshiaki、Narita Yukiya、Hara Hiroki、Ohta Takashi、Esaki Taito、Hamamoto Yasuo、Kato Ken、Yamamoto Yoshiyuki、Minashi Keiko、Ohtsubo Koushiro、Izawa Naoki、Kawakami Hisato、Kato Takeshi、Satoh Taroh、Okano Naohiro、Tsuji Akihito、Yamazaki Kentaro、Yoshino Takayuki、Maehara Yoshihiko、Oki Eiji
    • Journal Title

      British Journal of Cancer

      Volume: 129 Issue: 6 Pages: 1032-1039

    • DOI

      10.1038/s41416-023-02378-9

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii2023

    • Author(s)
      Maehara Yoshihiko、Oki Eiji、Kitao Hiroyuki、Iimori Makoto、Makino Kunio、Takechi Teiji、Sagara Takeshi、Miyadera Kazutaka、Matsuoka Kazuaki、Wakasa Takeshi、Ochiiwa Hiroaki、et al.
    • Journal Title

      International Journal of Clinical Oncology

      Volume: 28 Issue: 5 Pages: 613-624

    • DOI

      10.1007/s10147-023-02326-w

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
  • [Journal Article] The anti-tumor effect of trifluridine via induction of aberrant mitosis is unaffected by mutations modulating p53 activity2023

    • Author(s)
      Wakasa Takeshi、Iimori Makoto、Nonaka Kentaro、Oki Eiji、Maehara Yoshihiko、Kitao Hiroyuki et al.
    • Journal Title

      bioRxiv

      Volume: -

    • DOI

      10.1101/2023.08.30.555463

    • Related Report
      2023 Annual Research Report
  • [Journal Article] Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial2023

    • Author(s)
      Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T.
    • Journal Title

      British Journal of Cancer

      Volume: 128 Issue: 10 Pages: 1897-1905

    • DOI

      10.1038/s41416-023-02212-2

    • Related Report
      2022 Research-status Report
  • [Journal Article] CD44v3,8‐10 is essential for Slug‐dependent <i>vimentin</i> gene expression to acquire TGF‐β1‐induced tumor cell motility2022

    • Author(s)
      Qiu Shichao、Iimori Makoto、Edahiro Keitaro、Fujimoto Yoshiaki、Matsuoka Kazuaki、Oki Eiji、Maehara Yoshihiko、Mori Masaki、Kitao Hiroyuki
    • Journal Title

      Cancer Science

      Volume: 113 Issue: 8 Pages: 2654-2667

    • DOI

      10.1111/cas.15353

    • Related Report
      2022 Research-status Report
  • [Journal Article] Lack of impact of the <scp>ALDH2</scp> rs671 variant on breast cancer development in Japanese <scp>BRCA1</scp> /2‐mutation carriers2022

    • Author(s)
      Mori Tomoharu、Takata Minoru et al.
    • Journal Title

      Cancer Medicine

      Volume: 12 Issue: 6 Pages: 6594-6602

    • DOI

      10.1002/cam4.5430

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] p53機能欠損細胞におけるトリフルリジン誘導性DNA複製ストレスによる細胞毒性効果のメカニズム Mechanisms of cytotoxicity of trifluridine-induced DNA replication stress in p53 deficient cells2024

    • Author(s)
      飯森真人,若狹武司,野中謙太朗,菊竹智恵,須山幹太,小武内尚,松岡和明,沖英次,前原喜彦,北尾洋之
    • Organizer
      第83回 日本癌学会学術総会
    • Related Report
      2023 Annual Research Report
  • [Presentation] The significance of ATR as a therapeutic target in combination with DNA replication stress-inducing drugs2023

    • Author(s)
      北尾洋之、野中謙太朗、飯森真人、沖英次
    • Organizer
      19th Ataxia Telagiectasia Workshop
    • Related Report
      2022 Research-status Report
  • [Presentation] DNA複製ストレス誘導性抗がん剤との併用における治療標的としてのATR制御の意義2022

    • Author(s)
      飯森真人、野中謙太朗、北尾洋之
    • Organizer
      第45回日本分子生物学会年会
    • Related Report
      2022 Research-status Report
  • [Presentation] p53機能欠損細胞におけるトリフルリジン誘導性DNA複製ストレスによる細胞毒性効果のメカニズム2022

    • Author(s)
      飯森真人、若狹武司、野中謙太朗、菊竹千恵、須山幹太、小武内尚、松岡和明、沖英次、前原喜彦、北尾洋之
    • Organizer
      第81回日本癌学会学術総会
    • Related Report
      2022 Research-status Report
  • [Presentation] DNA複製ストレス誘導性抗がん剤との併用における治療標的としてのATR制御の意義2022

    • Author(s)
      野中謙太朗、飯森真人、北尾洋之
    • Organizer
      第81回日本癌学会学術総会
    • Related Report
      2022 Research-status Report
  • [Presentation] フッ化ピリミジン系抗癌剤をサイエンスする2022

    • Author(s)
      前原 喜彦
    • Organizer
      第122回日本外科学会定期学術集会
    • Related Report
      2022 Research-status Report

URL: 

Published: 2022-07-05   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi